Working At Ossium


Who We Are

At Ossium, we believe that science is humanity’s best weapon in the fight against disease, and we embrace the challenge of mobilizing the world’s healthcare ecosystem to win that fight. In pursuit of this goal, we empower our employees, maintain the highest standards of excellence, and are a force for good.

Kevin Caldwell

CEO, Co-Founder & President


Listen to Kevin Speak About Our Vision

Principles


The values we live by

Impact

We are mission-driven and results-oriented. We believe that a healthier world is a better one and that our work should drive positive change.

Truth

Embracing the truth empowers us to learn from both our successes and our mistakes. We follow the data wherever it leads.

Ownership

We hold ourselves and each other to the highest bar. We care deeply about the work we do and know that even the smallest details can make a difference.

Inside Look


Day in the Life

National Trainers

These donor tissue recovery experts work with our OPO partners to continuously improve our tissue recovery processes.  They are masters of Ossium’s recovery protocols and practices.

Cell Therapy Associates

These processing experts make our cell therapy products. They are skilled in tissue processing, cell processing, and cryopreservation.

Quality Control Associates

These laboratory experts ensure the quality of our final products always meet Ossium’s rigorous standards. They are adept in product testing, focused on quality, and dedicated to laboratory excellence.



Words from the Team

It is incredible to see Ossium growing and changing before your eyes. The tremendous achievements are owed to the unmatched leadership and to every single hardworking team member. The team's passion and drive to save lives radiates through the daily work. People at all levels are heard, supported, and make a recognizable difference. Each Ossie inspires me to be better and work harder. Working at Ossium is more than a job - it is a challenge, it is a family, it is fulfillment, it is world-changing.

Aubrey Sherry

Senior Manager, Quality Systems

Aubrey Sherry

Senior Manager, Quality Systems

I really appreciate that Ossium has challenged me in ways that totally throw me out of my comfort zone. It's a wonderful place to learn and grow.

Brian Johnstone

Vice President, Research

Brian Johnstone

Vice President, Research

For the past 20 years, Dr. Johnstone has been actively involved in translating adult stem cell therapies into treatments for a host of diseases affecting the major organs of the body. In 2004, he co-authored one of the first studies demonstrating the potential for treating cardiovascular diseases with novel adult stem cells isolated from fat.

Since then, Dr. Johnstone has continued to develop and test new medical uses for adult stem cells as part of his own research as well as in collaboration with international academic centers and pharma / biotech firms.

Outside of the research setting, Dr. Johnstone co-founded NeuroFx, an early-stage biotech firm developing a novel therapy for neurological disorders. Dr. Johnstone led the R&D program at NeuroFx for two years, where he was directly responsible for preclinical and chemistry, manufacturing, and controls development activities. He continues to act as an advisor for NeuroFx. Additionally, Dr. Johnstone has formed two other biotech companies, Chemigen, which is developing a small molecule drug for treating Lou Gehrig’s disease, and EmphyMab Biotech (now Allinaire), which is developing biologics to treat serious lung diseases.

Before becoming an entrepreneur, Dr. Johnstone was an early employee at Sangamo Biosciences for 6 years, where he managed the preclinical development program for their lead gene therapy candidate for cardiovascular diseases, which is currently in Phase II clinical testing. Dr. Johnstone received his Ph.D. from the University of Maryland, College Park, and completed a postdoctoral fellowship at the University of California, Los Angeles.

Meeting Erik a few years ago and exploring Ossium's mission is what motivated me to move from Europe and join Ossium. I am driven by developing new opportunities in cell therapy that save more lives, and being part of the amazing 'we can do it' Ossium team makes every day a joy.

Wa'el Al Rawashdeh

Vice President, Orthopedic Business Development

Wa'el Al Rawashdeh

Vice President, Orthopedic Business Development

Dr. Al Rawashdeh has an interdisciplinary career focusing on the clinical translation of cell therapies and development of molecular imaging platforms. Prior to joining Ossium, he held a number of critical roles at Miltenyi Biotec, a global market-leader in cell processing, that enabled the creation of a successful CAR T cell therapy program. Dr. Al Rawashdeh developed industry-leading non-clinical development (NCD) and molecular imaging platforms and led the in vivo NCD packages of the CAR T cell therapy program, which in 4 years resulted in 4 CIT approvals in Germany, 1 IND pivotal trial FDA application, and 1 successful approval of an ‘orphan drug’ by the EMA. Dr. Al Rawashdeh developed a novel animal model that permitted the approval of the first CAR T cell clinical trial in Europe targeting melanoma.

On the research front, Dr. Al Rawashdeh spearheaded the initiation of an industry-academia consortium that successfully secured a major grant of $1.6 million from the EU European Funding for Regional Development initiative to develop novel CAR T cell therapies against solid tumors and cell tracking strategies, and led the project up to the time of his departure in 2021, when he joined Ossium.

As a postdoc at RWTH Aachen University, Germany’s top engineering university, Dr. Al Rawashdeh co-developed novel optical imaging technology that convinced MiLabs, a global leader in molecular imaging, to adopt the technology and build and commercialize a hybrid tomography system that generated over $10 million in sales to date. Furthermore, on the basis of his original research and project design where he recruited industry partners from Germany, Italy and the UK, he secured a $1 million grant from the European Union’s European Commission in the highly competitive multi-country BioPhotonics call.

Dr. Al Rawashdeh completed his BS from California State University, Fresno, and his MSc and Ph.D. from RWTH Aachen University.



Open Positions

At Ossium, we’re always looking for talented, mission-driven people.